Division News

School of Medicine Office for Faculty Development has announced the next class in its ALICE program, a leadership development opportunity for mid-career women faculty in the School of Medicine. Five participants in the next class are from the Department of Medicine.

7 faculty from the Department of Medicine will participate in the School of Medicine's LEADER program.

Step by step, Gowthami Arepally has decrypted the molecular biology that produces heparin-induced thrombocytopenia (HIT), a sometimes fatal immune reaction to the  prescribed blood thinner.

The Duke Division of Hematology has announced that David Ginsburg, MD, will deliver the 2017 William H. Kane Hematology Lecture on Fri., Oct. 13, 2017 during Medicine Grand Rounds.

Grace Lee, MD, medical instructor in the Division of Hematology, has been selected to participate in the American Society of Hematology's 2017 Translational Research Training in Hematology Program.

8 faculty from the Department of Medicine will participate in the School of Medicine's LEADER program.

Brice Weinberg, MD, professor of medicine (Hematology) and immunology, is one of three Duke University faculty named Fellow of the American Association for the Advancement of Science (AAAS).

Fourteen faculty from the Department of Medicine were chosen as Duke Health Scholars and Duke Health Fellows. This inaugural program was created with a transfer of funds from the Duke University Health System. Its aim is to support the research efforts and enhance the academic success of early to mid-career clinician-scientists in School of Medicine clinical departments.

​Evan Sadler, MD, PhD, director of the Division of Hematology and Ira M. Lang Professor of Medicine at Washington University School of Medicine in St. Louis, visited the Division of Hematology earlier this month to deliver the second annual William H. Kane Hematology Lecture.

Thomas Ortel, MD, PhD, has received a funding award from the Patient-Centered Outcomes Research Institute (PCORI). Dr. Ortel will receive $15 million over five years for the project "Warfarin versus Direct Oral Anticoagulants for Secondary Prevention of Recurrent Venous Thromboembolism: A Randomized Comparative Effectiveness Trial."